Hunterdon Hematology Oncology
Hunterdon Hematology Oncology is a physician-owned community oncology and hematology practice in Flemington, NJ, delivering chemotherapy, immunotherapy, targeted therapy, clinical trials, and supportive care to cancer and blood-disorder patients across Central New Jersey.
- Company typePrivate
- Founded1990
- HeadquartersFlemington, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
What Hunterdon Hematology Oncology does
Hunterdon Hematology Oncology (HHO) is a privately held, physician-owned community oncology and hematology practice operating as an LLC out of Flemington, New Jersey, founded in 1990 and serving patients across Hunterdon, Warren, Somerset, and Mercer counties in Central New Jersey. The practice employs five board-certified hematologist-oncologists — Dr. Myron Bednar, Dr. Megha Shah, Dr. Swee Jian Ngeow, Dr. Waqas Rehman, and Dr. Kevin Wang — and six PA-Cs, operating from three locations: the main infusion center at 2100 Wescott Drive inside the Hunterdon Regional Cancer Center (HRCC), a second Flemington suite in the Doctor's Building at 1100 Wescott Drive, and a Hawk Pointe satellite in Washington, NJ. HHO is accredited by the American College of Surgeons' Commission on Cancer and by ACHC, distinctions held by roughly one in four cancer facilities nationally.
The practice delivers a full-service medical oncology and hematology portfolio spanning chemotherapy, immunotherapy (including certified PROVENGE/sipuleucel-T administration for advanced prostate cancer), personalized targeted therapy guided by next-generation sequencing and genetic tumor profiling, supportive care including the Paxman FDA-cleared scalp cooling system, and integrative oncology services (dietary, behavioral counseling, palliative care coordination). Differentiated clinical research is delivered through an ongoing partnership with Fox Chase Cancer Center, providing community access to National Cooperative Group trials such as GO42784, ASCENT-05, Briacell, BGB-A317-316, TAILOR, Biovica Divitum, and ULI-EAP-100, with Dr. Bednar serving as advisor to Fox Chase's extramural research program.
HHO's revenue model is fee-for-service medical practice billing through commercial insurance, Medicare, and Medicaid, supplemented by pharmaceutical-sponsored clinical trial income. Go-to-market is sales-led via referrals from Hunterdon Health Network primary care physicians and regional specialists, supported by direct patient intake through the HHO website, online appointment booking, and word-of-mouth. Operating infrastructure runs on NextGen Healthcare and MedFusion patient portals with InstaMed payment processing. The practice is privately held by its five physician partners with no PE, VC, or parent-company ownership disclosed.
Hunterdon Hematology Oncology firmographics
Firmographics- Name
- Hunterdon Hematology Oncology
- Legal name
- Hunterdon Hematology Oncology, LLC
- Website
- https://hhocancer.com
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Hunterdon Hematology Oncology is a physician-owned community oncology and hematology practice in Flemington, NJ, delivering chemotherapy, immunotherapy, targeted therapy, clinical trials, and supportive care to cancer and blood-disorder patients across Central New Jersey.
- Ownership category
- akta.pro rank
Hunterdon Hematology Oncology industry classification
Industry- Product category
- Oncology and Hematology Medical Services
- NAICS
- Offices of Physicians (62111), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093), Services-Health Services (8000)
- akta.pro industry
- Medical OncologyAmbulatory Oncology Centers (Outpatient Chemo/Radiation)Medical Hematology (Benign Hematology)Hospital-Integrated Cancer Centers (Acute Oncology Programs)
Keywords
Where Hunterdon Hematology Oncology is headquartered
LocationHeadquarters
- HQ city
- Flemington
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Hunterdon Hematology Oncology business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Medical Oncology Services: Billable medical services including consultations, chemotherapy infusions, immunotherapy treatments, and ongoing cancer care management billed through insurance plans and Medicare/Medicaid
- Clinical Trial Research: Participation in clinical trials with pharmaceutical company sponsorship and National Cancer Institute cooperative group research funding
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Standard oncology/hematology medical services billed via insurance |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Hunterdon Hematology Oncology product offering
Product offeringCore offering
Hunterdon Hematology Oncology provides community-based medical oncology and hematology services, including cancer diagnosis, chemotherapy administration, immunotherapy, personalized targeted therapy, and access to clinical trials. The practice operates an on-site infusion center and is co-located within the Hunterdon Regional Cancer Center, offering patients integrated access to surgical, radiation, and supportive oncology services across three New Jersey locations.
Product overview
Hunterdon Hematology Oncology is a community oncology group providing comprehensive cancer and blood disorder treatment services from its facilities in Flemington, New Jersey. The practice offers a unified portfolio of core treatment services including chemotherapy, immunotherapy, and personalized targeted therapy, supplemented by access to clinical trials through a partnership with Fox Chase Cancer Center. Supportive care is delivered through integrative oncology combining traditional medicine with complementary therapies, and the Paxman Scalp Cooling System for hair loss prevention during chemotherapy. The practice is uniquely positioned within the Hunterdon Regional Cancer Center, providing access to additional specialists, radiation oncology, physical therapy, genetic counseling, and laboratory and pharmacy services in one location.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Hair loss reduction: 50.5% of scalp cooling patients had less than 50% hair loss vs 0% without cooling
Companies that use Hunterdon Hematology Oncology
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Hunterdon Hematology Oncology technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature4 records
Hunterdon Hematology Oncology partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Hunterdon Regional Cancer Center (HRCC)coreHHO is uniquely positioned within the comprehensive Hunterdon Regional Cancer Center. This affiliation allows patients access to surgeons, radiation oncology, physical therapy, genetic counseling, and other supportive services in one location. The practice maintains its main office and infusion center within HRCC facilities.
- Fox Chase Cancer CentercorePartnership enables HHO to participate in Fox Chase Cancer Center clinical trials, allowing patients to receive cutting-edge treatments close to home rather than traveling to Philadelphia. Dr. Bednar serves as advisor for Fox Chase's extramural research program. The practice also maintains affiliation for clinical trial referrals and research collaboration.
- National Cooperative Groups ProgramminorDr. Bednar and Hunterdon Regional Cancer Center participate in research trials through the National Cooperative Groups Program, which coordinates multi-center clinical trials across institutions.
- Hunterdon Medical CentercoreIntegration with Hunterdon Medical Center for hospital-based services, surgery coordination, palliative care referrals, and comprehensive cancer program accreditation through Commission on Cancer.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Hunterdon Hematology Oncology competitors and assessment
Company assessmentBroad incumbents
- Memorial Sloan Kettering Cancer Center: Premier academic oncology center. While not a direct community competitor, MSK's regional care network competes for Central NJ patients willing to travel and serves as the upper-tier benchmark against which HHO's 'academic-level care close to home' positioning is measured.
- RWJBarnabas Health Oncology: Large NJ health system offering comprehensive oncology services including infusion, radiation, and clinical trials across multiple hospitals. Competes for the same Central NJ patient pool as HHO with broader service lines and hospital infrastructure.
- Fox Chase Cancer Center: NCI-designated Comprehensive Cancer Center and HHO's primary clinical trials partner. Comparable in oncology treatment offerings and physician training pedigree, but operates as an academic medical center rather than a community practice, with hospital-based and research-driven economics.
- Hackensack Meridian Health Cancer Care: Major NJ health system with multiple cancer centers offering medical oncology, infusion, and clinical trials. Competes with HHO for oncology patients in the northern and central NJ corridor with greater scale and broader service portfolio.
Others
- Hunterdon Medical Center: HHO's primary hospital partner and host facility within Hunterdon Regional Cancer Center. While not a direct oncology competitor, it provides the integrated infrastructure (surgery, radiation, ER, palliative care) that HHO's model depends on, making it a critical ecosystem participant.
Emerging players
- OneOncology: PE-backed platform aggregating independent community oncology practices nationwide. A potential acquirer or competitor to HHO; its growth trajectory signals where independent practices like HHO are likely to be pressured or consolidated.
- The US Oncology Network: Nation's largest network of community oncology practices, supported by McKesson. While not a single practice peer, US Oncology's affiliated practices represent HHO's most significant competitive and partnership model — many independent community oncology groups have joined or sold to this network.
Direct peers
- ASTERA Cancer Care: Large New Jersey-based community oncology practice offering medical oncology, hematology, and infusion services across multiple NJ locations. Directly comparable to HHO in specialty and geography, but at significantly greater scale with a broader physician roster.
- Regional Cancer Care Associates (RCCA): Multi-site community oncology practice serving New Jersey, Connecticut, and Maryland. Comparable to HHO in offering chemotherapy, immunotherapy, clinical trials, and supportive care in community settings, but with substantially greater geographic reach and scale.
- New Jersey Cancer Care: Community-based hematology/oncology practice in New Jersey offering chemotherapy, immunotherapy, and infusion services. Closely mirrors HHO's service model in the same regional market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Hunterdon Hematology Oncology compliance and trust
Trust signalCompliance2 records
Hunterdon Hematology Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hunterdon Hematology Oncology leadership team
Management profileNumber of profiles
Profiles11 records
Hunterdon Hematology Oncology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hunterdon Hematology Oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hunterdon Hematology Oncology
What does Hunterdon Hematology Oncology do?
Hunterdon Hematology Oncology provides community-based medical oncology and hematology services, including cancer diagnosis, chemotherapy administration, immunotherapy, personalized targeted therapy, and access to clinical trials. The practice operates an on-site infusion center and is co-located within the Hunterdon Regional Cancer Center, offering patients integrated access to surgical, radiation, and supportive oncology services across three New Jersey locations.
Is Hunterdon Hematology Oncology a public or private company?
Hunterdon Hematology Oncology is a private company. It is classified as management employee owned and is currently operating.
When was Hunterdon Hematology Oncology founded?
Hunterdon Hematology Oncology was founded in 1990. It employs 11 to 50 people.
Where is Hunterdon Hematology Oncology based?
Hunterdon Hematology Oncology is headquartered in Flemington, United States, in the North America region.
How does Hunterdon Hematology Oncology make money?
Two revenue lines are on record. Medical Oncology Services are the primary driver. The others are clinical Trial Research.
Who are Hunterdon Hematology Oncology's main competitors?
Broad incumbents on record are Memorial Sloan Kettering Cancer Center, RWJBarnabas Health Oncology, Fox Chase Cancer Center and Hackensack Meridian Health Cancer Care. Hunterdon Medical Center is listed as an others. Emerging players are OneOncology and The US Oncology Network. Direct peers are ASTERA Cancer Care, Regional Cancer Care Associates (RCCA) and New Jersey Cancer Care.
Does Hunterdon Hematology Oncology have an API?
No public API is recorded for Hunterdon Hematology Oncology.
What industry is Hunterdon Hematology Oncology in?
Hunterdon Hematology Oncology's product category is Oncology and Hematology Medical Services. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAFABAI, Ambulatory Oncology Centers (Outpatient Chemo/Radiation). Its NAICS code is 62111 and its SIC code is 8011.